FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor resnance	. 05								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Watts Ryan J.						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Denali Therapeutics Inc. [ DNLI ]								(Check all app X Direc		tor		10% (	Owner	
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 10/01/2021								X Officer (give title below) Other (specific below)  President and CEO						
	DUTH SAN RANCISCO CA 94080				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transaction Date				2. Transaction	n 2A. Deem Execution (ear) if any		emed		3. Transaction Code (Instr. 8)		4. Securities Acquir Disposed Of (D) (Ins		ired (A) or		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ion(s)			(Instr. 4)	
Common Stock 10/0				10/01/202	21				S <sup>(1)</sup>		3,304	D	\$49.3	38 <sup>(2)</sup>	2,15	5,063		T I	See footnote <sup>(3)</sup>	
Common Stock 10/01/20					21				S <sup>(1)</sup>		10,782	D	\$50.4	44 <sup>(4)</sup>	2,144,281		I		See footnote <sup>(3)</sup>	
Common Stock 10/01/2					21				S <sup>(1)</sup>		4,247	4,247 D \$50		9 <b>9</b> <sup>(5)</sup>	2,140,034				See footnote <sup>(3)</sup>	
Common Stock															151,	691 <sup>(6)</sup>		D		
		Tal	ole II	l - Derivati (e.g., pu							posed of, convertil				Owne	t				
	f 2. 3. Transaction 3A. Deemed			4. Trans	ransaction of Code (Instr. ) Se Ad (A Di of (Ir		Number		6. Date Exercisable Expiration Date (Month/Day/Year)		7. Title Amou Secur Under Deriva Secur	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of erivative ecurity estr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	ve es ially ng ed etion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exer	e rcisable	Expiration Date	Title	Amour or Number of Shares	er						

- 1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$48.85 to \$49.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 3. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- 4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$49.90 to \$50.895 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$50.90 to \$51.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

6. Includes 151,691 restricted stock units.

## Remarks:

/s/ Tyler Nielsen, by power of attorney

10/05/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.